Pierre-Henri is a European Patent Attorney with experience in intellectual property since 2017, spanning both in-house and private practice.
He previously worked as an in-house patent attorney at a major pharmaceutical company, focusing on nucleic acid-based therapeutics, including antisense oligonucleotides (ASOs) and RNA interference technologies such as siRNAs. He later joined a Scandinavian IP firm before moving to Zacco in 2026. His technical scope also includes enzyme-based technologies and PCR-related innovations, for which he has conducted multiple Freedom-to-Operate (FTO) analyses for a global leader in the PCR sector.
His practice covers the full patent lifecycle, including drafting, prosecution, and the preparation of validity and infringement opinions. Drawing on in-house experience, he advises on the alignment of patent strategy with clinical development and commercial objectives. He also has experience in opposition and appeal proceedings before the European Patent Office (EPO).
Pierre-Henri holds a Bachelor’s degree in Biochemistry and Molecular Biology and a Master’s degree in Biotechnology and Genomics. He was recognized as a Recommended Individual in the 2024 edition of IAM Patent 1000.
© 2026, Zacco A/S
